Short-term immunotherapy with allergoids and the adjuvant monophosphoryl lipid A. Results from a 3-year post-marketing surveillance study;Kurzzeit-immuntherapie mit allergoiden und dem adjuvans monophosphoryl-lipid A. Ergebnisse einer 3-jährigen praxisstudie

Allergologie

Volumn 30, Issue 2, 2007, Pages

  Zielen, S ^a   Metz, D ^b   Sommer, E ^c   Scherf, H P ^d  

^a GOETHE UNIVERSITY   (Germany)

^b Praxis für Dermatologie/Allergologie ^*  (Germany)

^c Praxis für Hals Nasen Ohren Heilkunde Allergologie   (Germany)

^d Praxisgemeinschaft Allgemeinmedizin/Innere Medizin   (Germany)

Author keywords

Adjuvant; Allergoids; Asthma; Conjunctivitis; Monophosphoryl lipid A; MPL ; Rhinitis; Short term immunotherapy

Indexed keywords

PHOSPHORYL LIPID A; POLLEN ANTIGEN; POLLINEX QUATTRO; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; HAY FEVER; HUMAN; IMMUNOTHERAPY; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; POLLEN ALLERGY; POSTMARKETING SURVEILLANCE; SWELLING; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VACCINATION;

EID: 33847718714     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Alonso P.L., J. Sacarlal, J.J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M.M. Navia, S. Corachan, M. Ceuppens, M.C. Dubois, M.A. Demoitié, F. Dubovsky, C. Menéndez, N. Tornieporth, W.R. Ballou, R. Thompson, J. Cohen: Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411-1420(2004).
2. Bousquet J., R.F. Lackey, H.-J. Malling: Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 53 (Suppl.), 1-42(1998).
3. Bousquet J., P. van Cauwenberge, N. Khaltaev: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108 (Suppl. 5), S147-S334 (2001).
4. Cohn J. R., A. Pizzi: Determinants of patient compliance with allergen immunotherapy. J. Allergy Clin. Immunol. 91, 734-737 (1992).
5. Drachenberg K.J., A.W. Wheeler, P. Stuebner, F. Horak: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A reduces allergic symptoms after only four preseasonal injections. Allergy 56, 498-505 (2001).
6. Drachenberg K.J., M. Heinzkill, E. Urban: Kurzzeit-Immuntherapie mit Baumpollenallergoiden und dem Adjuvans Monophosphoryl Lipid-A. Allergologie 25, 466-474 (2002).
7. Drachenberg K.J., S. Pröll, E. Urban, M. Heinzkill: Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int. Rev. Allergol. Clin. Immunol. 8, 219-223 (2002).
8. Drachenberg K.J., S. Pröll, E. Urban: Kurzzeit-Immuntherapie - Ergebnisse einer Anwendungsbeobachtung. Allergologie 25, S8-S14 (2002).
9. Drachenberg K.J., M. Heinzkill, E. Urban, S.R. Woroniecki: Efficacy and tolerability of short-term immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. 31, 270-277 (2003).
10. Durham S.R., S.J. Till: Immunologie changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 102, 157-164(1998).
11. Eng P., H.E. Gnehm, H.I. Joller: Klinische und immunogene Wirkung der saisonalen Hyposensibilisierung bei Kindern mit Pollinosis. Monatsschr. Kinderheilkd. 142, 616-622 (1994).
12. Fiedler G.: Die Anwendung einer Kurzzeit-Immuntherapie mit Pollenallergoiden und dem Adjuvans MPL in einer dermatologischen Praxis. Allergo J. 11 (Suppl. 1), 46 (2002).
13. Frank E.: Multicenterstudie zur Bewertung von Wirksamkeit und Verträglichkeit einer Hyposensibilisierungs-Behandlung mit Allergoid-Depot mit Kurzzeit-Dosierungsschema (Allergovit Gräser-/ Roggenpollen). Allergologie 10, 23-30 (1987).
14. Hofman T.: The results of the specific immunotherapy by Allergovit in patients with pollen allergy (in Polnisch). Pol. Merk. Lek. 3, 183-186 (1997).
15. Kleine-Tebbe J., K.-C. Bergmann, F. Friedrichs, T. Fuchs, K. Jung, L. Klimek, J. Kühr, W. Lässig, U. Lepp, B. Niggemann, J. Rakoski, W. Rebien, H. Renz, J. Saloga, J. Simon, H. Sitter, C. Virchow, M. Worm: Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J. 15, 56-74 (2006).
16. Loidolt D., E. Frank: Ergebnisse einer dreijährigen kontrollierten Hyposensibilisierung von Pollinotikern mit modifizierten und nicht modifizierten Gramineen-Extrakten. Allergologie 13, 21-28(1990).
17. Lower T., J. Henry, L. Mandik, J. Janosky, G.A, Friday: Compliance with allergen immunotherapy. Ann. Allergy 70, 480-482 (1993).
18. Moran D.M., A.W. Wheeler, B.C. Overell, S.R. Woroniecki: Chemical modification of crude timothy grass extract. 3. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int. Arch. Allergy Appl. Immunol. 54, 315-321 (1977).
19. Overell B.C., D.A. Spackmann, A.W. Wheeler, P. Pfeiffer: Standardisation of glutaraldehyde-modified, tyrosine-adsorbed allergen extracts. Allergologie 14, 110-115(1991).
20. Puggioni F., J.N. Francis, S.R. Durham: Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of TH1 responses. Allergy 60, 678-684 (2005).
21. Schlinzig EM. : Short-term immunotherapy with tyrosine-adsorbed allergoids adjuvanted by monophosphoryl lipid A in the practice of an allergologist. Allergy 57(Suppl. 73), 8135(2002).
22. Stuck B.A., S. Schneider-Gene, L. Klimek, D. Schäfer, K. Hörmann: Short-term immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL) influences cytokine production of peripheral T cells in patients with allergic rhinitis. ACI Int. 16, 60-64 (2003).
23. Thoelen S., P. van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoumi, A. Meheus: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16, 708-714 (1998).
24. Thum-Oltmer S., D. Ullrich, H. Meyer, D. Müller-Scheven: Kurzzeit-Immuntherapie mit Allergoiden. Allergologie 28, 391-400 (2006).
25. Wheeler A.W., I.H. Taylor, V. Mehta, J. Mitchell, D. Reece, K.J. Drachenberg: Tyrosin-Allergoid Baumpollen. Standardisierung mittels relevanter Methoden. Allergo J. 2, 71-75 (1993).
26. Wheeler A.W., J.S. Marshall, J.T. Ulrich: A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 126, 135-139 (2001).